Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Very likely. Smart move now is to hold shares in Aphria for the ride back up to the $20's. One big deal away from that happening.
Aphria stock was $20 a few months ago. If they can produce 255,000 kg this year I suspect they will be touching that share price again.
Aphria stock looks like it double bottomed and is back in an uptrend. A nice deal would spike this for sure. Seems very undervalued given that they are likely to be one of the top cannabis growers this year...if they do in fact produce 255,000 kg of weed.....seems very likely.
Recent Aphria presentation had all Pepsi products showing when talking about branding. Good bet that Pepsi might be in the picture here.
Alpha Holdings is listed as an activist investor in Oncosec. I think they want to take control of the company or at least influence the future direction, hopefully with capital investment. Expanding the pipe to lung cancer with funding would be big. Alpha mentions expanding Oncosec to lung cancer on their website....if this is true the stock will be moving higher in 2019. Looks like a bloodbath right now in the markets but nothing has changed with Oncosec's direction. I see PISCES getting early approval...the bar is low. TNBC is undervalued and any indication of future sucess in this indication will have the shares poping. 2019 should be a good year. Data coming soon....not worried at all about delisting. If Alpha thought Oncosec was on their way to being delisted they would not have completed the 2nd tranche.
I can't imagine that Alpha Holdings would agree to be severly diluted unless there is more to this story that the market does not know yet. Undisclosed agreement for possible pipeline expansion (lung cancer, brain cancer...etc.) ....with exclusive licensing or merger agreement.....something must be happening behind closed doors.
Yes, I did read that. Out of our control until more data comes out...the trend needs to reverse again.
This share price is insanity right now. Gotta be tax selling.
Oncosec needs to do something to support the stock and shareholders. Presenting premature data at SITC was clearly not in the best interest of shareholders. Insider buying for more than a few thousand shares would be nice.....say a few hundred thousand shares would show more confidence. I am shocked we are trading at this level Alpha invested at $1.50 and the ATM is not being executed because of the drop in price. We need a recovery ASAP!
Oncosec earnings report out. They have not executed the $30 mil ATM and are saying they are under no obligation to execute it....nice to hear this. I think they will either cancel it or potpone any new offering when they have matured data to benefit from it without diluting current sheraholder.
Oncosec science is solid. The market is simply smacking ONCS around during tax loss selling season. Anybody care about the science Oncosec is focused on, namely IL12 with checkpoint therapy should read this: https://www.cell.com/immunity/fulltext/S1074-7613(18)30439-4
Alot of buying and also alot of selling happening today. Tug of War. People selling every pop for tax losses because most people in this have a loss from the massive drop after SITC. January first is a new ballgame. People will move right back into ONCS when we get closer to data again in both PISCES and TNBC cobo studies. Nothing has changed really. ONCS is on their way to two FDA approvals. TNBC combo is recruiting faster than the TNBC pilot study did and that is a good sign.
Some large buys at .82
TNBC data today could surprise with more off-protocol patient info. Anything positve in this regard could send ONCS right back over $1. Break that mark and I see momentum quickly reversing and the shares begin a climb higher again.
I believe that Lung Cancer will be the indication slated for Oncosec's PIIM multi-gene construct....and it seems that Alpha Holdings will be supporting this new trial upcoming....March 3rd according to their pr yesterday.
Alpha Holdings seems to have a strong sense of ownership towards Oncosec at this point. They have listed 18 of Oncosec publications on their website....and feel it is their right to publicize Oncosec developments even before Oncosec does....can't help but read into this.
Alpha Holdings will very likely increase their stake in Oncosec to their full allowance under the agreement between the two companies. Alpha ngotiating an Oncosec board seat means they have strong interest in Oncosec. Alpha is going to launch a U.S. subsidiary in San Francisco and it seems they have plans for Oncosec being square in the middle of this plan. Lung cancer is a huge market and Alpha Holdings will likely be funding this with Oncosec. This is getting very interesting.
Looks like legit news to me. Translating the Korean info on the alphachips.com site reveals Alpha Holdings will be creating a U.S. subsidiary in San Francisco and expand Oncosec's pipeline into lung cancer....a huge market. They are firm believers in Oncosec tech. I suspect ONCS shares should pop tomorrow on this news.
Lung cancer is the largest market in cancer for Merck so it has been my hope that Oncosec would venture into this indication even though it is not mentioned on their website. If you would kindly post the translated announcement that would be great. I would expect Oncosec to pr this as it would be very important news.
Maybe Dr. Pierce was inspired to teach the next wave of future scientists....that is usually why one becomes a teacher.
His work at Oncosec was done. No longer needed. The combo data will speak for itself once it is matured. Pierce had the opportunity to work for Fred Hutchinson Cancer Research Center and the Scientific Director of the Immunopathology Lab....and also from what I know he teaches at his Alma Mater. He is a scientist and a scientist does not sit still.
Yes, and exit strategy and/or licensing deal for ONCS is still the ultimate goal here.
These results are why Dr. Robert Pierce who spear-headed the Keytruda program at Merck, went to work for Oncosec to help move combo checkpoint therapy to the next level. Of all the small companies to go to he chose Oncosec. PISCES is the culmination of that decision. FDA approval or two coming next year for Oncosec in melanoma and TNBC.
TAVO mono is significant evidence that Oncosec therapy works without a checkpoint. Big Pharma will take notice... this is concrete final data and it stacks up well with checkpoint monotherapy....without toxic side effects. Just wait til next year when the PIIM multi-gene construct rolls out. If Oncosec can produce greater than 30% BORR with no side effects they could be on the road to displacing checkpoint therapy.....so now who is going to jump in and buyout ONCS tech to gain control?
TAVO monotherapy stacks up well to checkpoint monotherapy BORR....so we can only assume that in combination TAVO will improve checkpoint therapy. Early PISCES data already suggests cold turmor "terminal-last resort" patients can be converted. Big Pharma will want this.
The next data update will be very important with the rest of these first 21 patients fully accounted for at 12 weeks. More mature data will pull us out of the dumps. Right now we have people selling for tax reasons....time of the season. I am holding strong and long.
The SITC poster patient profile has information on the first 21 patients and the first nine are mostly further along in their disease with multiple prior lines of treatment.
That is exactly the best takeaway from the fireside chat today. Some of these PD patients also had tumor regression but stppoed treatment due to new lesions and trial criteria. If you look at each case and photos, these patients have very severe melanoma. Of the 21 total patients treated so far the first 9 have had more rounds of previous therapy and their disease is further along. As data matures I think we will see a greater percentage of responders simply because the first 9 were the worst of the worst. Some of the next 11 patients treated are at an earlier stage of their disease and more likely to have a better response. Rigorous criteria....but Oncosec strategy is to get an approval by way of an accelerated approval...and 20% BORR in this "salvage" population will get it done. That means "predicted" peak revenues of $350 million in melanoma is very likely after an approval....and I smell licensing deal or buyout if they clear the first approval hurdle....that would be validation of immunopulse.
Drop in the morning, bounce in the afternoon on high volume. Accumulation by TUTES, nothing more. 2019 will see ONCS rise again into PISCES and TNBC matured data.
We are obviously seeing an accumulation phase right now. Strong egaul-sided volume last few daya. ONCS will likely be over $1 within the next week.
Maybe a surprise announcement coming.
Would be nice if a few more patients went off protocol and got Keytruda as a comparison to the two patients that got Opdivo. At the very least it will be interesting to see an update of the two patients treated with Opdivo after ep-il12. Seems very positive that 2 of 2 patients treated with an anti-pd1 both responded. Decent data should reinstill faith in Oncosec while we wait for the next update in the PISCES trial.
I believe the odds are still pretty good for Oncosec once the data for PISCES and also TNBC is mature. Algazi said the 1 PD patient is expected to become a responder in the PISCES trial....so that would put us at 33% response rate.
Alain Algazi said they expect the 1 SD patient to also go on to be a responder with continued treatment. 21 patients are enrolled but only 9 were at the point to be scanned. That means 11 more patients will be evaluable soon. As the Maxim analyst said, "let's see what the data looks like at 24 weeks". Too soon to really get the full picture yet. The market is being way too harsh. Also TNBC should be enrolling and that will be another shot on goal. 2 robust responses in the pilot study is a very good sign that Oncosec is not just a one trick pony. When trial data in both studies are more mature the market will react better in my opinion. Looking into the future, the multi-gene construct should grab market interest when we get any news on that front. Oncosec jumped the gun presenting data too soon at SITC. I am taking the opportunity to add shares down at this level.
EMHTF earnings the end of November. Any indication of revenue increase and this is going to pop. Just a matter of time.
PISCES trial is just the tip of the iceberg. The multi-gene construct will be market disrupting tech. Stay tuned in 2019. Oncosec and Avacta are two small companies with huge future vision. Not surprising Asian interest has floated into Oncosec via Alpha Holdings.
Nope, no gap to fill here. Check: https://gapchecker.com/#
I quick added more shares at the open this morning at $2.60. Emerald Health is predicted to be the next Billion Dollar Brand in Canada. It is very obvious The AMERICAN CANNABIS SUMMIT video is talking about Emerald Health as their Branding pick. Avtar was mentioned as well as references to EMHTF management background from....Eli Lilly, Coke, Kraft Philip Morris.....very Obvious (EMHTF).
I added more shares this afternoon on the dip. Too good to pass up. EMHTF is too undervalued to ignore in the cannabis space. They aspire to be the next GW pharma. If they wind up with a share price north of $100 in the next few years, people will be slapping themselves in the face for not taking the risk and grabbing some shares way down here in the $2 to $3 level.
That is what I meant, The Ontario Cannabis Store...online...https://ocs.ca/#/verify-age